PT1530465E - Processo para produção de uma preparação lipossomal catiónica que compreende um composto lipofílico - Google Patents

Processo para produção de uma preparação lipossomal catiónica que compreende um composto lipofílico Download PDF

Info

Publication number
PT1530465E
PT1530465E PT03740355T PT03740355T PT1530465E PT 1530465 E PT1530465 E PT 1530465E PT 03740355 T PT03740355 T PT 03740355T PT 03740355 T PT03740355 T PT 03740355T PT 1530465 E PT1530465 E PT 1530465E
Authority
PT
Portugal
Prior art keywords
cationic liposomal
liposomal preparation
production
lipophilic compound
well
Prior art date
Application number
PT03740355T
Other languages
English (en)
Portuguese (pt)
Inventor
Winter Prof Dr Gerhard
Carsten Mundus
Christian Welz
Oliver Schramel
Heinrich Haas
Thomas Fichert
Brita Schulze
Toralf Peymann
Friedrich Gruber
Michael Teifel
Uwe Michaelis
Original Assignee
Medigene Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384485&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1530465(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP02018724A external-priority patent/EP1374864A1/en
Application filed by Medigene Ag filed Critical Medigene Ag
Publication of PT1530465E publication Critical patent/PT1530465E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
PT03740355T 2002-06-26 2003-06-26 Processo para produção de uma preparação lipossomal catiónica que compreende um composto lipofílico PT1530465E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39124502P 2002-06-26 2002-06-26
US39124602P 2002-06-26 2002-06-26
EP02018724A EP1374864A1 (en) 2002-06-26 2002-08-21 Amphiphilic taxane compositions
EP03004744 2003-03-04

Publications (1)

Publication Number Publication Date
PT1530465E true PT1530465E (pt) 2010-01-05

Family

ID=43384485

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03740355T PT1530465E (pt) 2002-06-26 2003-06-26 Processo para produção de uma preparação lipossomal catiónica que compreende um composto lipofílico

Country Status (12)

Country Link
US (4) US7794747B2 (https=)
EP (4) EP1530465B2 (https=)
JP (1) JP4975964B2 (https=)
AT (1) ATE444062T1 (https=)
AU (1) AU2003280505B2 (https=)
CA (1) CA2491216C (https=)
CY (1) CY1118670T1 (https=)
DE (1) DE60329497D1 (https=)
DK (2) DK1530465T4 (https=)
ES (1) ES2331791T5 (https=)
PT (1) PT1530465E (https=)
WO (1) WO2004002468A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508245A (ja) 2001-10-19 2005-03-31 イノベイティブ コンストラクション アンド ビルディング マテリアルズ， エルエルシー 感染性空気伝搬微生物に対する防御力を有する抗病原性空気濾過媒体および空気処理デバイス
EP1530465B2 (en) 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
US6902797B2 (en) * 2002-11-12 2005-06-07 Innovative Construction And Building Materials Gypsum-based composite materials reinforced by cellulose ethers
WO2005039533A1 (en) * 2003-10-15 2005-05-06 Medigene Ag Method of administering cationic liposomes comprising an active drug
EP1676569A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
EP1896007B1 (en) 2005-05-04 2014-03-19 Medigene AG Method of administering a cationic liposomal preparation comprising paclitexel
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
BRPI0709075A2 (pt) 2006-03-20 2011-10-11 Medigene Ag tratamento de cáncer de mama triplo receptor negativo
US20110002851A1 (en) * 2006-11-03 2011-01-06 Medigene Ag Cationic Colloidal Carriers for Delivery of Active Agents to the Blood-Brain Barrier in the Course of Neuroinflammatory Diseases
US20090319020A1 (en) * 2007-01-23 2009-12-24 Dtherapeutics, Llc Devices, systems, and methods for promoting endothelialization
EP2146692A1 (en) * 2007-03-19 2010-01-27 Fresenius Kabi Oncology Limited Proliposomal and liposomal compositions
US20120100067A1 (en) * 2008-04-04 2012-04-26 Medigene Ag Solubilisation Method
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
WO2010108934A1 (en) * 2009-03-25 2010-09-30 Novartis Ag Pharmaceutical composition containing a drug and sirna
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CA2781527C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
DE102011114951A1 (de) 2011-10-06 2013-04-11 Forschungszentrum Jülich GmbH Molekülmischung, umfassend eine amphipathische Molekülsorte A, welche im hydrophilen Bereich elne positive Gesamtladung aufweist und eine amphipathische Molekülsorte B sowie ein Polyphenol C, Verfahren zur Herstellung der Molekülmischung und deren Verwendung
CN103110931B (zh) * 2013-03-19 2015-08-19 广州迈达康医药科技有限公司 制备罗咪酯肽脂质体的方法
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
US9895313B2 (en) * 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
US11298318B2 (en) 2015-04-13 2022-04-12 Fountain Technologies International, Llc One-step method for production of ultra-small lipid structures
US20180361342A1 (en) * 2015-12-08 2018-12-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for Preparing Liposome
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
CN105853403B (zh) * 2016-05-09 2019-03-29 上海天氏利医药科技有限公司 一种紫杉醇棕榈酸酯脂质体及其制备方法
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
US20210236664A1 (en) * 2018-04-25 2021-08-05 The Johns Hopkins University Alpha particle formulations for treatment of solid tumors
CN114144198A (zh) 2019-07-16 2022-03-04 科斯塔治疗公司 膜脂包覆的纳米颗粒的制备方法
CN110974972B (zh) * 2019-12-03 2023-01-20 沈阳药科大学 难溶性药物的弱酸性衍生物及其脂质体制剂
CN110981837A (zh) * 2019-12-03 2020-04-10 沈阳药科大学 紫杉醇弱酸性衍生物主动载药脂质体及其制备与应用
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
EP4015634A1 (en) 2020-12-15 2022-06-22 Sylentis, S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
EP4419064A4 (en) * 2021-10-22 2025-08-27 Ohio State Innovation Foundation COMPOSITIONS AND METHODS FOR ADMINISTERING ACTIVE AGENTS COMPRISING NUCLEIC ACIDS
US20240108579A1 (en) 2021-12-31 2024-04-04 Chengdu Biostar Pharmaceuticals, Ltd. Utidelone liposome composition, and preparation method therefor and use thereof
WO2024044370A1 (en) * 2022-08-25 2024-02-29 Ohio State Innovation Foundation Compositions and methods for the delivery of active agents including nucleic acids
WO2024160190A1 (zh) 2023-01-31 2024-08-08 石药集团中奇制药技术（石家庄）有限公司 紫杉醇阳离子脂质体治疗肿瘤的用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
ATE194767T1 (de) 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
AU5612694A (en) * 1992-11-27 1994-06-22 Napro Biotherapeutics, Inc. Injectable composition
JPH06211645A (ja) * 1993-01-14 1994-08-02 Mitsubishi Kasei Corp リポソーム凍結乾燥製剤
WO1994026254A1 (en) 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
EP1118325B2 (en) 1993-07-29 2010-01-06 The United States of America, represented by the Secretary, Department of Health and Human Services Use of Paclitaxel and its derivatives in the manufacture of a medicament for treating restenosis.
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
DE4430593C2 (de) 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
DE4432378A1 (de) 1994-09-12 1996-03-14 Bayer Ag Injizierbare liposomale Arzneizubereitungen
AU3740997A (en) 1996-08-26 1998-03-19 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
CA2269758C (en) * 1996-10-22 2008-01-08 Hermes Biosciences, Inc. Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation
AU4966597A (en) 1996-11-19 1998-06-10 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
JP2002508765A (ja) * 1997-06-23 2002-03-19 アルザ コーポレイション リポソーム被包ポリヌクレオチド組成物および方法
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
ES2251134T3 (es) * 1999-06-08 2006-04-16 Gentium S.P.A. Uso de complejos entre liposomas cationicos y polidesoxirribonucleotidos como medicamentos.
BR0012624B1 (pt) 1999-07-15 2011-08-09 métodos para a preparação de agentes terapêuticos envolvidos por lipìdeos.
GB9918429D0 (en) 1999-08-04 1999-10-06 Novartis Ag Organic compounds
KR100591767B1 (ko) * 1999-09-09 2006-06-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 탁산의 맥관형성 혈관 전달을 위한 양이온성 리포좀
WO2001025223A1 (en) * 1999-10-06 2001-04-12 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
DE60123583T2 (de) 2000-02-04 2007-08-09 Lipoxen Technologies Ltd. Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
PL366025A1 (pl) * 2000-05-03 2005-01-24 Munich Biotech Ag Kationowe środki diagnostyczne, obrazujące i terapeutyczne, zasocjowane z uaktywnionymi miejscami wnaczyniach
AU2001275423B2 (en) 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
US6680068B2 (en) * 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
EP1530465B2 (en) * 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.

Also Published As

Publication number Publication date
ATE444062T1 (de) 2009-10-15
DK1530465T4 (en) 2016-03-21
AU2003280505A1 (en) 2004-01-19
US8663606B2 (en) 2014-03-04
CY1118670T1 (el) 2017-07-12
DK1530465T3 (da) 2010-02-01
EP2108362A2 (en) 2009-10-14
US20140205657A1 (en) 2014-07-24
CA2491216C (en) 2012-01-03
US20110038926A1 (en) 2011-02-17
US9238021B2 (en) 2016-01-19
EP1530465B1 (en) 2009-09-30
EP2286795B1 (en) 2016-10-26
JP4975964B2 (ja) 2012-07-11
ES2331791T5 (es) 2016-01-21
DE60329497D1 (de) 2009-11-12
US20050202076A1 (en) 2005-09-15
EP2108362A3 (en) 2010-12-15
JP2005535730A (ja) 2005-11-24
EP1530465A1 (en) 2005-05-18
EP2277507A1 (en) 2011-01-26
US7794747B2 (en) 2010-09-14
US8075913B2 (en) 2011-12-13
EP1530465B2 (en) 2015-12-16
US20120087975A1 (en) 2012-04-12
EP2286795A1 (en) 2011-02-23
DK2286795T3 (en) 2017-02-06
AU2003280505B2 (en) 2009-01-15
WO2004002468A1 (en) 2004-01-08
ES2331791T3 (es) 2010-01-15
CA2491216A1 (en) 2004-01-08
EP2108362B1 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
PT1530465E (pt) Processo para produção de uma preparação lipossomal catiónica que compreende um composto lipofílico
BRPI0318811B8 (pt) derivados de ciclohexanol espirocíclicos
BRPI0611350B8 (pt) formulação, seus usos e seu processo de fabricação,e artigo de fabricação
BR0107425A (pt) Processo para a preparação compostos de derivados de ácido 3-hidróxi picolìnico e uso dos compostos
BRPI0510599A (pt) compostos, processo para a preparação dos mesmos, composição farmacêutica, uso de um composto, e método para o tratamento e a profilaxia de doenças
PT1258476E (pt) Derivados de alfa-amino-acidos, processo para sua preparacao assim como a sua utilizacao como inibidores de dipeptidil-peptidase iv (dpp iv).
EP1726299A3 (en) Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
WO2003014079A8 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
DK1453810T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
ECSP044973A (es) Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion
BR0108826B1 (pt) processo para a produção de uma zeólita contendo titánio, zeólita contendo titánio assim obtida, processo para a epoxidação de olefinas e uso da referida zeólita.
WO2001079174A8 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
GT200500394A (es) 18-metil-19-nor-17-oregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen
BRPI0417360A (pt) método para a preparação de multiparticulados farmacêuticos
WO2005121078A3 (de) Substituierte cyclopenten-verbindungen
BRPI0012475B1 (pt) composto derivado de titánio, seu processo de preparação e utilização, bem como composição para uso oral compreendendo o mesmo.
ATE528301T1 (de) Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
WO2004069145A3 (en) Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
BRPI0410482A (pt) composto, processo para preparar o mesmo, agente adequado para combater fungos nocivos, e, processo para combater fungos nocivos fitopatogênicos
EA200300771A1 (ru) Новая соль бензоилгуанидина
BRPI0512967A (pt) processo de preparação de derivados de hidroxiacetofenona, processo de preparação de derivados de 4-oxo-4h-cromen-3-carbaldeìdo, derivados de hidroxiacetofenona, derivados de 4-oxo-4h-cromen-3-carbaldeìdo, composições farmacêuticas compreendendo os mesmos e usos dos referidos derivados na preparação de composições farmacêuticas
PT1270576E (pt) Compostos de 3-fenil-3, 7-diazabiciclo-[3,3,1]nonano, assim como processo para sua producao e medicamentos contendo estes compostos
WO2002085877A3 (en) Processes and intermediates for preparing benzyl substituted epoxides
WO2004033416A3 (de) Carboxyalkoxy-substituierte acyl-carboxyphenyl-harnstoffderivate, verfahren zu ihre herstellung und ihre verwendung als arzneimittel
PL367981A1 (en) A process for the preparation of the 14beta-hydroxy-baccatin iii-1,14-carbonate